Description

OVITRELLE 250MG INJ

Indications

OVITRELLE 250MG INJ is primarily indicated for the treatment of infertility in women. It is used in assisted reproductive technology (ART) protocols, including in vitro fertilization (IVF) and ovulation induction. The active ingredient, choriogonadotropin alfa, is a recombinant form of human chorionic gonadotropin (hCG) that mimics the natural hormone responsible for triggering ovulation. OVITRELLE is prescribed to help stimulate the ovaries to produce mature eggs, facilitating conception.

Mechanism of Action

The mechanism of action of OVITRELLE involves the stimulation of ovarian follicles to mature and release eggs. Choriogonadotropin alfa binds to the luteinizing hormone (LH) receptor in ovarian tissues, mimicking the action of endogenous LH. This binding leads to the final maturation of ovarian follicles and induces ovulation. By administering OVITRELLE, healthcare providers aim to synchronize ovulation with the timing of insemination or embryo transfer, thereby enhancing the chances of successful conception.

Pharmacological Properties

OVITRELLE contains choriogonadotropin alfa, which is a glycoprotein hormone composed of two subunits: alpha and beta. The pharmacokinetics of OVITRELLE demonstrate that after subcutaneous administration, it is rapidly absorbed into the systemic circulation. The bioavailability is high, and peak plasma concentrations are typically reached within 24 hours. The elimination half-life of choriogonadotropin alfa is approximately 24 hours, allowing for effective dosing schedules. The drug is primarily metabolized by the liver and excreted via the kidneys.

Contraindications

OVITRELLE is contraindicated in several conditions. It should not be used in patients with a known hypersensitivity to choriogonadotropin alfa or any of its components. Additionally, it is contraindicated in cases of uncontrolled adrenal gland disorders, ovarian cysts not associated with polycystic ovary syndrome (PCOS), and certain tumors of the reproductive system. Pregnant women should not use OVITRELLE, as it may cause adverse effects on the fetus. Patients with a history of thromboembolic events should also avoid this medication due to the potential risk of complications.

Side Effects

Like all medications, OVITRELLE may cause side effects, although not everyone will experience them. Common side effects include injection site reactions, abdominal pain, nausea, and headache. More serious side effects can occur, such as ovarian hyperstimulation syndrome (OHSS), which can lead to severe abdominal pain, fluid accumulation, and in rare cases, hospitalization. Other potential side effects include mood swings, breast tenderness, and weight gain. Patients should be advised to report any severe or persistent side effects to their healthcare provider.

Dosage and Administration

The recommended dosage of OVITRELLE varies depending on the specific treatment protocol and the individual patient’s response. Typically, a single dose of 250 micrograms (1 vial) is administered subcutaneously, usually 36 hours after the last dose of gonadotropins. It is essential to follow the healthcare provider’s instructions regarding timing and dosage to optimize the chances of successful ovulation and conception. Patients should be educated on proper injection techniques to minimize discomfort and ensure effective administration.

Interactions

OVITRELLE may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. It is crucial for patients to inform their healthcare providers about all medications they are currently taking, including over-the-counter drugs and herbal supplements. Specific interactions may occur with other hormonal therapies, and caution should be exercised when used concurrently with anticoagulants or medications that affect liver metabolism. Regular monitoring and adjustments may be necessary to ensure patient safety and treatment effectiveness.

Precautions

Before initiating treatment with OVITRELLE, healthcare providers should conduct a thorough assessment of the patient’s medical history and current health status. Special precautions should be taken in patients with a history of ovarian hyperstimulation syndrome, as they may be at increased risk. Patients should be monitored closely for signs of OHSS, particularly in the days following administration. Additionally, the use of OVITRELLE should be approached with caution in patients with pre-existing conditions such as thyroid disorders or adrenal insufficiency. Regular follow-up appointments are essential to evaluate the patient’s response to treatment and adjust the protocol as necessary.

Clinical Studies

Clinical studies have demonstrated the efficacy of OVITRELLE in inducing ovulation and improving pregnancy rates in women undergoing assisted reproductive technologies. In randomized controlled trials, OVITRELLE has been shown to be effective in triggering ovulation in women with various underlying causes of infertility. The results indicate that the use of OVITRELLE, in conjunction with controlled ovarian stimulation, significantly increases the likelihood of successful ovulation and subsequent conception. These studies support the safety profile of OVITRELLE, with a manageable side effect profile when used appropriately.

Conclusion

OVITRELLE 250MG INJ is a valuable therapeutic option for women experiencing infertility, particularly in the context of assisted reproductive technologies. Its mechanism of action, pharmacological properties, and clinical efficacy make it a critical component in ovulation induction protocols. While generally well-tolerated, healthcare providers must remain vigilant regarding contraindications, potential side effects, and patient-specific factors that may influence treatment outcomes. By ensuring appropriate use and monitoring, OVITRELLE can significantly enhance the chances of successful conception for many women seeking to start or expand their families.